Advocates of chimpanzee research claim the genetic similarity of humans and chimpanzees make them an indispensable research tool to combat human diseases. Given that cancer is a leading cause of human death worldwide, one might expect that if chimpanzees were needed for, or were productive in, cancer research, then they would have been widely used. This comprehensive literature analysis reveals that chimpanzees have scarcely been used in any form of cancer research, and that chimpanzee tumours are extremely rare and biologically different from human cancers. Often, chimpanzee citations described peripheral use of chimpanzee cells and genetic material in predominantly human genomic studies. Papers describing potential new cancer therapies noted significant concerns regarding the chimpanzee model. Other studies described interventions that have not been pursued clinically. Finally, available evidence indicates that chimpanzees are not essential in the development of therapeutic monoclonal antibodies. It would therefore be unscientific to claim that chimpanzees are vital to cancer research. On the contrary, it is reasonable to conclude that cancer research would not suffer, if the use of chimpanzees for this purpose were prohibited in the US. Genetic differences between humans and chimpanzees, make them an unsuitable model for cancer, as well as other human diseases.
VermijP. (2003). Europe's last research chimps to retire. Nature Medicine9, 981.
4.
de KokW. (2002). Dutch Lab Chimps to be Retired. Available at: http://www.ippl.org/2002-dutch-chimps.php (Accessed 10.06.09). Summerville, SC, USA: International Primate Protection League.
VandeBergJ.L. & ZolaS.M. (2005). A unique bio-medical resource at risk. Nature, London437, 30–32.
7.
BaileyJ. & BalcombeJ. (2007). Chimpanzee Research: An Examination of its Contribution to Biomedical Knowledge and Efficacy in Combating Human Diseases, 47 pp. Available at: http://www.releasechimps.org/pdfs/chimp-efficacy-paper-main.pdf (Accessed 10.06.09). Boston, MA, USA: New England Anti-Vivisection Society (Project R&R).
8.
KnightA. (2007). The poor contribution of chimpanzee experiments to biomedical progress. Journal of Applied Animal Welfare Science10, 281–308.
9.
BaileyJ. (2008). An assessment of the role of chimpanzees in AIDS vaccine research. ATLA36, 381–428.
10.
BradshawG.A., CapaldoT., LindnerL. & GrowG. (2008). Building an inner sanctuary: complex PTSD in chimpanzees. Journal of Trauma & Dissociation9, 9–34.
11.
BradshawG.A., CapaldoT., LindnerL. & GrowG. (2009). Developmental context effects on bi-cultural post-trauma self repair in chimpanzees. Developmental Psychology45, in press.
12.
AlbrehtT., McKeeM., AlexeD.M., ColemanM.P. & Martin-MorenoJ.M. (2008). Making progress against cancer in Europe in 2008. European Journal of Cancer44, 1451–1456.
13.
JemalA., SiegelR., WardE., HaoY., XuJ., MurrayT. & ThunM.J. (2008). Cancer statistics, 2008. CA: A Cancer Journal for Clinicians58, 71–96.
14.
BrittenR.J. (2002). Divergence between samples of chimpanzee and human DNA sequences is 5%, counting indels. Proceedings of the National Academy of Sciences of the USA99, 13633–13635.
15.
VarkiA. & AltheideT.K. (2005). Comparing the human and chimpanzee genomes: searching for needles in a haystack. Genome Research15, 1746–1758.
Toft 2ndJ.D. & MacKenzieW.F. (1975). Endometrial stromal tumor in a chimpanzee. Veterinary Pathology12, 32–36.
18.
ChandlerF.W., McClureH.M., CampbellW.G. & WattsJ.C. (1976). Pulmonary pneumocystosis in nonhuman primates. Archives of Pathology & Laboratory Medicine100, 163–167.
19.
GrahamC.E. & McClureH.M. (1976). Sertoli-Leydig cell tumor in a chimpanzee. Laboratory Animal Science26, 948–950.
20.
GrahamC.E. & McClureH.M. (1977). Ovarian tumors and related lesions in aged chimpanzees. Veterinary Pathology14, 380–386.
21.
AmyxH.L., SalazarA.M., NewsomeD.A., GibbsC.J.J. & GajdusekD.C. (1982). Nasopharyngeal carcinoma with intracranial extension in a chimpanzee. Journal of the American Veterinary Medical Association181, 1425–1426.
22.
BarriereH., LitouxP., Le LayM., BureauB., StalderJ.F. & DrenoB. (1984). [Cutaneous achromia and malignant melanoma]. Annales de Dermatologie et de Venereologie111, 991–996.
23.
PorterB.F., GoensS.D., BraskyK.M. & HubbardG.B. (2004). A case report of hepatocellular carcinoma and focal nodular hyperplasia with a myelolipoma in two chimpanzees and a review of spontaneous hepatobiliary tumors in non-human primates. Journal of Medical Primatology33, 38–47.
24.
MuchmoreE., PopperH., PetersonD.A., MillerM.F. & LiebermanH.M. (1988). Non-A, non-B hepatitis-related hepatocellular carcinoma in a chimpanzee. Journal of Medical Primatology17, 235–246.
25.
AbeK., KageiN., TeramuraY. & EjimaH. (1993). Hepatocellular carcinoma associated with chronic Schistosoma mansoni infection in a chimpanzee. Journal of Medical Primatology22, 237–239.
26.
GreenwoodA.G., LoweJ.W. & GauntL. (1995). Renal carcinoma in a chimpanzee (Pan troglodytes). Veterinary Record137, 380–381.
27.
BinhazimA.A., LeeD.R., BernackyB.J. & RizviT.A. (1997). Spontaneous anaplastic large cell lymphoma in a chimpanzee: a clinicopathological and immunohistochemical study. Journal of Medical Primatology26, 260–266.
28.
StarostM.F. & MartinoM. (2002). Adenoma of the gallbladder in a chimpanzee (Pan troglodytes). Journal of Zoo & Wildlife Medicine33, 176–177.
29.
SaturdayG.A., LasotaJ., FrostD., BraskyK.B., HubbardG. & MiettinenM. (2005). KIT-positive gastrointestinal stromal tumor in a 22-year-old male chimpanzee (Pan troglodytes). Veterinary Pathology42, 362–365.
30.
KlopfleischR., LangnerC., von FelbertI., RudnickJ.C. & TeifkeJ.P. (2007). Nevus lipomatosus cutaneus superficialis (Hoffmann-Zurhelle) in a chimpanzee (Pan troglodytes). Journal of Medical Primatology36, 57–60.
31.
Van RanstM., FuseA., FitenP., BeukenE., PfisterH., BurkR.D. & OpdenakkerG. (1992). Human papillomavirus type 13 and pygmy chimpanzee papillomavirus type 1: comparison of the genome organizations. Virology190, 587–596.
32.
ThakralD., DobbinsJ., DevineL. & KavathasP.B. (2008). Differential expression of the human CD8beta splice variants and regulation of the M-2 isoform by ubiquitination. Journal of Immunology180, 7431–7442.
33.
HedlundM., TangvoranuntakulP., TakematsuH., LongJ.M., HousleyG.D., KozutsumiY., SuzukiA., Wynshaw-BorisA., RyanA.F., GalloR.L., VarkiN. & VarkiA. (2007). N-glycolylneuraminic acid deficiency in mice: implications for human biology and evolution. Molecular & Cellular Biology27, 4340–4346.
34.
VarkiA. (2001). Loss of N-glycolylneuraminic acid in humans: Mechanisms, consequences, and implications for hominid evolution. American Journal of Physical Anthropology Suppl. 33, 54–69.
35.
ZhuQ.Y., LiuY. & ZhuN.S. (2007). [Molecular evolution of GAGE gene family]. Yi Chuan29, 559–564.
36.
BaysalB.E., LawrenceE.C. & FerrellR.E. (2007). Sequence variation in human succinate dehydrogenase genes: evidence for long-term balancing selection on SDHA. BMC Biology5, 12.
37.
BaysalB.E., FerrellR.E., Willett-BrozickJ.E., LawrenceE.C., MyssiorekD., BoschA., van der MeyA., TaschnerP.E., RubinsteinW.S., MyersE.N., Richard 3rdC.W., CornelisseC.J., DevileeP. & DevlinB. (2000). Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science, New York287, 848–851.
38.
NiemannS. & MullerU. (2000). Mutations in SDHC cause autosomal dominant paraganglioma, type 3. Nature Genetics26, 268–270.
39.
AstutiD., LatifF., DallolA., DahiaP.L., DouglasF., GeorgeE., SkoldbergF., HusebyeE.S., EngC. & MaherE.R. (2001). Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. American Journal of Human Genetics69, 49–54.
40.
BaysalB.E., Willett-BrozickJ.E., LawrenceE.C., DrovdlicC.M., SavulS.A., McLeodD.R., YeeH.A., BrackmannD.E., Slattery 3rdW.H., MyersE.N., FerrellR.E. & RubinsteinW.S. (2002). Prevalence of SDHB, SDHC, and SDHD germline mutations in clinic patients with head and neck paragangliomas. Journal of Medical Genetics39, 178–183.
41.
BaysalB.E., Willett-BrozickJ.E., FilhoP.A., LawrenceE.C., MyersE.N. & FerrellR.E. (2004). An Alu-mediated partial SDHC deletion causes familial and sporadic paraganglioma. Journal of Medical Genetics41, 703–709.
42.
BayleyJ.P., DevileeP. & TaschnerP.E. (2005). The SDH mutation database: an online resource for succinate dehydrogenase sequence variants involved in pheochromocytoma, paraganglioma and mitochondrial complex II deficiency. BMC Medical Genetics6, 39.
43.
SchiaviF., BoedekerC.C., BauschB., PeczkowskaM., GomezC.F., StrassburgT., PawluC., BuchtaM., SalzmannM., HoffmannM.M., BerlisA., BrinkI., CybullaM., MuresanM., WalterM.A., ForrerF., ValimakiM., KaweckiA., SzutkowskiZ., SchipperJ., WalzM.K., PignyP., BautersC., Willet-BrozickJ.E., BaysalB.E., JanuszewiczA., EngC., OpocherG. & NeumannH.P. (2005). Predictors and prevalence of paraganglioma syndrome associated with mutations of the SDHC gene. Journal of the American Medical Association294, 2057–2063.
44.
MullerG.A., HeissigF. & EngelandK. (2007). Chimpanzee, orangutan, mouse, and human cell cycle promoters exempt CCAAT boxes and CHR elements from interspecies differences. Molecular Biology & Evolution24, 814–826.
45.
FernandoH., ReszkaA.P., HuppertJ., LadameS., RankinS., VenkitaramanA.R., NeidleS. & BalasubramanianS. (2006). A conserved quadruplex motif located in a transcription activation site of the human c-kit oncogene. Biochemistry45, 7854–7860.
46.
ChenY.T., IseliC., VendittiC.A., OldL.J., SimpsonA.J. & JongeneelC.V. (2006). Identification of a new cancer/testis gene family, CT47, among expressed multicopy genes on the human X chromosome. Genes Chromosomes & Cancer45, 392–400.
47.
GiladY., OshlackA., SmythG.K., SpeedT.P. & WhiteK.P. (2006). Expression profiling in primates reveals a rapid evolution of human transcription factors. Nature, London440, 242–245.
48.
PuenteX.S., VelascoG., Gutierrez-FernandezA., BertranpetitJ., KingM.C. & Lopez-OtinC. (2006). Comparative analysis of cancer genes in the human and chimpanzee genomes. BMC Genomics7, 15.
49.
McCutcheonI.E., HentschelS.J., FullerG.N., JinW. & CoteG.J. (2004). Expression of the splicing regulator polypyrimidine tract-binding protein in normal and neoplastic brain. Neurooncology6, 9–14.
50.
RomanelliM.G., LorenziP. & MorandiC. (2005). Identification and analysis of the human neural polypyrimidine tract binding protein (nPTB) gene promoter region. Gene356, 11–18.
51.
JohneR., EnderleinD., NieperH. & MullerH. (2005). Novel polyomavirus detected in the feces of a chimpanzee by nested broad-spectrum PCR. Journal of Virology79, 3883–3887.
52.
PavlicekA., NoskovV.N., KouprinaN., BarrettJ.C., JurkaJ. & LarionovV. (2004). Evolution of the tumor suppressor BRCA1 locus in primates: implications for cancer predisposition. Human Molecular Genetics13, 2737–2751.
53.
HuttleyG.A., EastealS., SoutheyM.C., TesorieroA., GilesG.G., McCredieM.R., HopperJ.L. & VenterD.J. (2000). Adaptive evolution of the tumour suppressor BRCA1 in humans and chimpanzees. Australian Breast Cancer Family Study. Nature Genetics25, 410–413.
BarbulescuM., TurnerG., SeamanM.I., DeinardA.S., KiddK.K. & LenzJ. (1999). Many human endogenous retrovirus K (HERV-K) proviruses are unique to humans. Current Biology9, 861–868.
56.
TarzamiS.T., KringsteinA.M., ConteR.A. & VermaR.S. (1997). Unique genomic sequences in human chromosome 16p are conserved in the great apes. Molecular & General Genetics253, 512–514.
57.
ThoravalD., AsakawaJ., KodairaM., ChangC., RadanyE., KuickR., LambB., RichardsonB., NeelJ.V., GloverT. & HanashS. (1996). A methylated human 9-kb repetitive sequence on acrocentric chromosomes is homologous to a sub-telomeric repeat in chimpanzees. Proceedings of the National Academy of Sciences of the USA93, 4442–4447.
58.
DumontM., FrankD., MoisanA.M., TranchantM., SoucyP., BretonR., LabrieF., TavtigianS.V. & SimardJ. (2004). Structure of primate and rodent orthologs of the prostate cancer susceptibility gene ELAC2. Biochimica et Biophysica Acta1679, 230–247.
59.
KulskiJ.K., LimC.P., DunnD.S. & BellgardM. (2003). Genomic and phylogenetic analysis of the S100A7 (Psoriasin) gene duplications within the region of the S100 gene cluster on human chromosome 1q21. Journal of Molecular Evolution56, 397–406.
60.
MorganK., ConklinD., PawsonA.J., SellarR., OttT.R. & MillarR.P. (2003). A transcriptionally active human type II gonadotropin-releasing hormone receptor gene homolog overlaps two genes in the antisense orientation on chromosome 1q.12. Endocrinology144, 423–436.
61.
DarbyS., StockleyJ., KhanM.M., RobsonC.N., LeungH.Y. & GnanapragasamV.J. (2007). Expression of GnRH type II is regulated by the androgen receptor in prostate cancer. Endocrine-related Cancer14, 613–624.
62.
ZhangJ. & RosenbergH.F. (2002). Diversifying selection of the tumor-growth promoter angio-genin in primate evolution. Molecular Biology & Evolution19, 438–445.
63.
SaleS., SungR., ShenP., YuK., WangY., DuranG.E., KimJ.H., FojoT., OefnerP.J. & SikicB.I. (2002). Conservation of the class I beta-tubulin gene in human populations and lack of mutations in lung cancers and paclitaxel-resistant ovarian cancers. Molecular Cancer Therapeutics1, 215–225.
64.
SinkovicsJ.G. & HorvathJ.C. (1999). Kaposi's sarcoma: breeding ground of herpesviridae — A tour de force over viral evolution (review). International Journal of Oncology14, 615–646.
65.
GreensillJ., SheldonJ.A., MurthyK.K., BessonetteJ.S., BeerB.E. & SchulzT.F. (2000). A chimpanzee rhadinovirus sequence related to Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8: increased detection after HIV-1 infection in the absence of disease. AIDS14, F129–35.
66.
KiyosawaK., DaemerR.J., HeL.F., BoninoF., ProzeskyO.W. & PurcellR.H. (1985). The spectrum of complement-fixing antinuclear antibodies in patients with hepatocellular carcinoma. Hepatology5, 548–555.
67.
GerberP., PritchettR.F. & KieffE.D. (1976). Antigens and DNA of a chimpanzee agent related to Epstein-Barr virus. Journal of Virology19, 1090–1099.
68.
GerberP., KalterS.S., SchidlovskyG., PetersonW.D.J. & DanielM.D. (1977). Biologic and antigenic characteristics of Epstein-Barr virus-related Herpesviruses of chimpanzees and baboons. International Journal of Cancer20, 448–459.
69.
SmithG.C., HelmkeR.J., BarkerS.T., KalterS.S. & HeberlingR.L. (1976). Oncornavirus-like particles in baboon type C virus-infected chimpanzee lung cells (SFRE:CL-1). Journal of the National Cancer Institute56, 1059–1061.
70.
MuldersT.M., BruningP.F. & BonfrerJ.M. (1990). Prostate-specific antigen (PSA). A tissue-specific and sensitive tumor marker. European Journal of Surgical Oncology16, 37–41.
71.
KarrJ.F., KantorJ.A., HandP.H., EggenspergerD.L. & SchlomJ. (1995). The presence of prostate-specific antigen-related genes in primates and the expression of recombinant human prostate-specific antigen in a transfected murine cell line. Cancer Research55, 2455–2462.
72.
BoyleP., LembachK.J. & WetzelG.D. (1993). The B5 monoclonal human autoantibody binds to cell surface TNF alpha on human lymphoid cells and cell lines and appears to recognize a novel epitope. Cellular Immunology152, 569–581.
73.
MocellinS. & NittiD. (2008). TNF and cancer: the two sides of the coin. Frontiers in Bioscience13, 2774–2783.
74.
SethiG., SungB. & AggarwalB.B. (2008). TNF: a master switch for inflammation to cancer. Frontiers in Bioscience13, 5094–5107.
75.
HundsbergerH., VerinA., WiesnerC., PflugerM., DuleboA., SchuttW., LastersI., MannelD.N., WendelA. & LucasR. (2008). TNF: a moonlighting protein at the interface between cancer and infection. Frontiers in Bioscience13, 5374–5386.
76.
MartinezJ., DugaiczykL.J., ZielinskiR. & DugaiczykA. (2001). Human genetic disorders, a phylogenetic perspective. Journal of Molecular Biology308, 587–596.
77.
GibbonsR. & DugaiczykA. (2005). Phylogenetic roots of Alu-mediated rearrangements leading to cancer. Genome48, 160–167.
78.
HwuH.R., RobertsJ.W., DavidsonE.H. & BrittenR.J. (1986). Insertion and/or deletion of many repeated DNA sequences in human and higher ape evolution. Proceedings of the National Academy of Sciences of the USA83, 3875–3879.
79.
JurkaJ., KrnjajicM., KapitonovV.V., StengerJ.E. & KokhanyyO. (2002). Active Alu elements are passed primarily through paternal germlines. Theoretical Population Biology61, 519–530.
80.
LiuG., ZhaoS., BaileyJ.A., SahinalpS.C., AlkanC., TuzunE., GreenE.D. & EichlerE.E. (2003). Analysis of primate genomic variation reveals a repeat-driven expansion of the human genome. Genome Research13, 358–368.
81.
GibbonsR., DugaiczykL.J., GirkeT., DuistermarsB., ZielinskiR. & DugaiczykA. (2004). Distinguishing humans from great apes with AluYb8 repeats. Journal of Molecular Biology339, 721–729.
82.
KatohM. & KatohM. (2007). Comparative integromics on non-canonical WNT or planar cell polarity signaling molecules: transcriptional mechanism of PTK7 in colorectal cancer and that of SEMA6A in undifferentiated ES cells. International Journal of Molecular Medicine20, 405–409.
83.
KatohM. & KatohM. (2007). Integrative genomic analyses on HES/HEY family: Notch-independent HES1, HES3 transcription in undifferentiated ES cells, and Notch-dependent HES1, HES5, HEY1, HEY2, HEYL transcription in fetal tissues, adult tissues, or cancer. International Journal of Oncology31, 461–466.
84.
KatohM. & KatohM. (2007). Comparative integromics on JMJD1C gene encoding histone demethylase: conserved POU5F1 binding site elucidating mechanism of JMJD1C expression in undifferentiated ES cells and diffuse-type gastric cancer. International Journal of Oncology31, 219–223.
85.
KatohY. & KatohM. (2007). Comparative genomics on PROM1 gene encoding stem cell marker CD133. International Journal of Molecular Medicine19, 967–970.
86.
KatohM. & KatohM. (2007). Conserved POU/OCT- and GATA-binding sites in 5'-flanking promoter region of mammalian WNT8B orthologs. International Journal of Oncology30, 1273–1277.
87.
KatohM. & KatohM. (2007). AP1- and NF-kappaB-binding sites conserved among mammalian WNT10B orthologs elucidate the TNFalpha-WNT10B signaling loop implicated in carcinogenesis and adipogenesis. International Journal of Molecular Medicine19, 699–703.
88.
KatohM. & KatohM. (2007). Comparative integromics on FZD7 orthologs: conserved binding sites for PU.1, SP1, CCAAT-box and TCF/LEF/SOX transcription factors within 5'-promoter region of mammalian FZD7 orthologs. International Journal of Molecular Medicine19, 529–533.
89.
KatohY. & KatohM. (2007). Conserved POU-binding site linked to SP1-binding site within FZD5 promoter: Transcriptional mechanisms of FZD5 in undifferentiated human ES cells, fetal liver/spleen, adult colon, pancreatic islet, and diffuse-type gastric cancer. International Journal of Oncology30, 751–755.
90.
KatohM. & KatohM. (2007). STAT3-induced WNT5A signaling loop in embryonic stem cells, adult normal tissues, chronic persistent inflammation, rheumatoid arthritis and cancer (Review). International Journal of Molecular Medicine19, 273–278.
91.
KatohM. & KatohM. (2006). NUMB is a break of WNT-Notch signaling cycle. International Journal of Molecular Medicine18, 517–521.
92.
KatohY. & KatohM. (2006). Canonical WNT signaling pathway and human AREG. International Journal of Molecular Medicine17, 1163–1166.
93.
KatohY. & KatohM. (2006). Comparative integromics on Angiopoietin family members. International Journal of Molecular Medicine17, 1145–1149.
94.
KatohY. & KatohM. (2006). Comparative integromics on VEGF family members. International Journal of Oncology28, 1585–1589.
95.
KatohY. & KatohM. (2006). Comparative integromics on BMP/GDF family. International Journal of Molecular Medicine17, 951–955.
96.
KatohM. & KatohM. (2006). Comparative integromics on Eph family. International Journal of Oncology28, 1243–1247.
KatohM. & KatohM. (2006). Notch ligand, JAG1, is evolutionarily conserved target of canonical WNT signaling pathway in progenitor cells. International Journal of Molecular Medicine17, 681–685.
99.
KatohY. & KatohM. (2006). FGF signaling inhibitor, SPRY4, is evolutionarily conserved target of WNT signaling pathway in progenitor cells. International Journal of Molecular Medicine17, 529–532.
100.
KatohY. & KatohM. (2006). WNT antagonist, SFRP1, is Hedgehog signaling target. International Journal of Molecular Medicine17, 171–175.
101.
KatohY. & KatohM. (2005). Comparative genomics on Sonic hedgehog orthologs. Oncology Reports14, 1087–1090.
102.
MaedaN. & KimH.S. (1990). Three independent insertions of retrovirus-like sequences in the haptoglobin gene cluster of primates. Genomics8, 671–683.
103.
BonnerT.I., O'ConnellC. & CohenM. (1982). Cloned endogenous retroviral sequences from human DNA. Proceedings of the National Academy of Sciences of the USA79, 4709–4713.
104.
SongB., JavanbakhtH., PerronM., ParkD.H., StremlauM. & SodroskiJ. (2005). Retrovirus restriction by TRIM5alpha variants from Old World and New World primates. Journal of Virology79, 3930–3937.
105.
BrownP., NemoG. & GajdusekD.C. (1978). Human foamy virus: further characterization, seroepidemiology, and relationship to chimpanzee foamy viruses. Journal of Infectious Diseases137, 421–427.
106.
BieniaszP.D., WeissR.A. & McClureM.O. (1995). Cell cycle dependence of foamy retrovirus infection. Journal of Virology69, 7295–7299.
107.
KaymanS.C., WuZ., ReveszK., ChenH., KopelmanR. & PinterA. (1994). Presentation of native epitopes in the V1/V2 and V3 regions of human immunodeficiency virus type 1 gp120 by fusion glycoproteins containing isolated gp120 domains. Journal of Virology68, 400–410.
108.
HahmS.H., YiY., LeeD.K., NohM.J., YunL., HwangS. & LeeK.H. (2004). Construction of retro-viral vectors with enhanced efficiency of transgene expression. Journal of Virological Methods121, 127–136.
109.
LeendertzF.H., JunglenS., BoeschC., FormentyP., Couacy-HymannE., CourgnaudV., PauliG. & EllerbrokH. (2004). High variety of different simian T-cell leukemia virus type 1 strains in chimpanzees (Pan troglodytes verus) of the Taï National Park, Côte d'Ivoire. Journal of Virology78, 4352–4356.
110.
LangloisR.G., BigbeeW.L. & JensenR.H. (1985). Flow cytometric characterization of normal and variant cells with monoclonal antibodies specific for glycophorin A. Journal of Immunology134, 4009–4017.
111.
LindeskogM., MedstrandP., CunninghamA.A. & BlombergJ. (1998). Coamplification and dispersion of adjacent human endogenous retroviral HERV-H and HERV-E elements; presence of spliced hybrid transcripts in normal leukocytes. Virology244, 219–229.
112.
AlterH.J., EichbergJ.W., MasurH., SaxingerW.C., GalloR., MacherA.M., LaneH.C. & FauciA.S. (1984). Transmission of HTLV-III infection from human plasma to chimpanzees: an animal model for AIDS. Science, New York226, 549–552.
113.
ZhouE.M., ChanhT.C., DreesmanG.R., KandaP. & KennedyR.C. (1987). Immune response to human immunodeficiency virus. In vivo administration of anti-idiotype induces an anti-gp160 response specific for a synthetic peptide. Journal of Immunology139, 2950–2956.
114.
DowellB.L., TuckF.L., BorowitzM.J., LeBienT.W. & MetzgarR.S. (1984). Phylogenetic distribution of a 24,000 dalton human leukemia-associated antigen on platelets and kidney cells. Developmental & Comparative Immunology8, 187–195.
115.
LapinB.A., VoevodinA.F., IndzhiiaL.V., IakovlevaL.I. & GalloR. (1983). [Etiological aspects of leukemias in primates including man]. Byulleten Eksperimental noi Biologii i Meditsiny96, 14–16.
116.
MiyazawaM., Tsuji-KawaharaS. & KanariY. (2008). Host genetic factors that control immune responses to retrovirus infections. Vaccine26, 2981–2996.
117.
HasenkrugK.J. & DittmerU. (2007). Immune control and prevention of chronic Friend retro-virus infection. Frontiers in Bioscience12, 1544–1551.
118.
KarpasA. (2004). Human retroviruses in leukaemia and AIDS: reflections on their discovery, biology and epidemiology. Biological Reviews of the Cambridge Philosophical Society79, 911–933.
119.
SpieringsD.C., de VriesE.G., VellengaE., van den HeuvelF.A., KoornstraJ.J., WesselingJ., HollemaH. & de JongS. (2004). Tissue distribution of the death ligand TRAIL and its receptors. Journal of Histochemistry & Cytochemistry52, 821–831.
120.
BalyasnikovaI.V., YeomansD.C., McDonaldT.B. & DanilovS.M. (2002). Antibody-mediated lung endothelium targeting: in vivo model on primates. Gene Therapy9, 282–290.
121.
PecherG. & FinnO.J. (1996). Induction of cellular immunity in chimpanzees to human tumor-associated antigen mucin by vaccination with MUC-1 cDNA-transfected Epstein-Barr virus-immortalized autologous B cells. Proceedings of the National Academy of Sciences of the USA93, 1699–1704.
122.
Barratt-BoyesS.M., VladA. & FinnO.J. (1999). Immunization of chimpanzees with tumor antigen MUC1 mucin tandem repeat peptide elicits both helper and cytotoxic T-cell responses. Clinical Cancer Research5, 1918–1924.
123.
Barratt-BoyesS.M., KaoH. & FinnO.J. (1998). Chimpanzee dendritic cells derived in vitro from blood monocytes and pulsed with antigen elicit specific immune responses in vivo. Journal of Immunotherapy21, 142–148.
124.
SoaresM.M., MehtaV. & FinnO.J. (2001). Three different vaccines based on the 140-amino acid MUC1 peptide with seven tandemly repeated tumor-specific epitopes elicit distinct immune effector mechanisms in wild-type versus MUC1-transgenic mice with different potential for tumor rejection. Journal of Immunology166, 6555–6563.
125.
AbbenanteG. & FairlieD.P. (2005). Protease inhibitors in the clinic. Medicinal Chemistry1, 71–104.
126.
QianM., BaiS.A., BrogdonB., WuJ.T., LiuR.Q., CovingtonM.B., VaddiK., NewtonR.C., FosslerM.J., GarnerC.E., DengY., MaduskuieT., TrzaskosJ., DuanJ.J., DeciccoC.P. & ChristD.D. (2007). Pharmacokinetics and pharmacodynamics of DPC 333 ((2R)-2-((3R)-3-amino-3 {4-[2-methyl-4-quinolinyl methoxy] phenyl}-2-oxopyrrolidinyl)-N-hydroxy-4-methylpentan amide), a potent and selective inhibitor of tumor necrosis factor alpha-converting enzyme in rodents, dogs, chimpanzees, and humans. Drug Metabolism & Disposition35, 1916–1925.
127.
HarpprechtJ., JonkerM., PodzuweitH.G., HansmannM.L., TreumerJ., EcksteinV., van EerdP.C. & Muller-RuchholtzW. (1990). Human monoclonal antibody Ha6D3, a candidate for treatment of leukaemia? In vitro reactivity of Ha6D3 with leukaemic cells and in vivo applications in a chimpanzee. British Journal of Cancer. Supplement10, 44–47.
128.
SakuraiF. (2008). Development and evaluation of a novel gene delivery vehicle composed of adenovirus serotype 35. Biological & Pharmaceutical Bulletin31, 1819–1825.
129.
SakuraiF., KawabataK. & MizuguchiH. (2007). Adenovirus vectors composed of subgroup B adenoviruses. Current Gene Therapy7, 229–238.
130.
SkogJ., EdlundK., BergenheimA.T. & WadellG. (2007). Adenoviruses 16 and CV23 efficiently transduce human low-passage brain tumor and cancer stem cells. Molecular Therapy15, 2140–2145.
131.
VarnavskiA.N., SchliengerK., BergelsonJ.M., GaoG.P. & WilsonJ.M. (2003). Efficient transduction of human monocyte-derived dendritic cells by chimpanzee-derived adenoviral vector. Human Gene Therapy14, 533–544.
132.
RinaldoC.R. (2009). Dendritic cell-based human immunodeficiency virus vaccine. Journal of Internal Medicine265, 138–158.
133.
DuncanC. & RoddieH. (2008). Dendritic cell vaccines in acute leukaemia. Best Practice & Research. Clinical Haematology21, 521–541.
134.
Engell-NoerregaardL., HansenT.H., AndersenM.H., Thor StratenP. & SvaneI.M. (2009). Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters. Cancer Immunology, Immunotherapy58, 1–14.
135.
de GruijlT.D., van den EertweghA.J., PinedoH.M. & ScheperR.J. (2008). Whole-cell cancer vaccination: from autologous to allogeneic tumor-and dendritic cell-based vaccines. Cancer Immunology, Immunotherapy57, 1569–1577.
TackenP.J., TorensmaR. & FigdorC.G. (2006). Targeting antigens to dendritic cells in vivo. Immunobiology211, 599–608.
139.
OnaitisM., KaladyM.F., PruittS. & TylerD.S. (2002). Dendritic cell gene therapy. Surgical Oncology Clinics of North America11, 645–660.
140.
DutcherJ. (2002). Current status of interleukin-2 therapy for metastatic renal cell carcinoma and metastatic melanoma. Oncology (Williston Park)16, 4–10.
ShanafeltA.B., LinY., ShanafeltM.C., ForteC.P., Dubois-StringfellowN., CarterC., GibbonsJ.A., ChengS.L., DelariaK.A., FleischerR., GreveJ.M., GundelR., HarrisK., KellyR., KohB., LiY., LantzL., MakP., NeyerL., PlymM.J., RoczniakS., SerbanD., ThriftJ., TsuchiyamaL., WetzelM., WongM. & ZolotorevA. (2000). A T-cell-selective interleukin 2 mutein exhibits potent antitumor activity and is well tolerated in vivo. Nature Biotechnology18, 1197–1202.
143.
MargolinK., AtkinsM.B., DutcherJ.P., ErnstoffM.S., Smith 2ndJ.W., ClarkJ.I., BaarJ., SosmanJ., WeberJ., LathiaC., BrunettiJ., CihonF. & SchwartzB. (2007). Phase I trial of BAY 50-4798, an interleukin-2-specific agonist in advanced melanoma and renal cancer. Clinical Cancer Research13, 3312–3319.
144.
RitterG. & LivingstonP.O. (1991). Ganglioside antigens expressed by human cancer cells. Seminars in Cancer Biology2, 401–409.
145.
StuhlmillerG.M., RobersonK.M. & SeiglerH.F. (1989). Serological response of non-human primates to human melanoma disialoganglioside GD3. Cancer Immunology, Immunotherapy29, 205–210.
146.
ChapmanP.B. (2003). Vaccinating against GD3 ganglioside using BEC2 anti-idiotypic monoclonal antibody. Current Opinion in Investigational Drugs4, 710–715.
147.
ChapmanP.B., WilliamsL., SalibiN., HwuW.J., KrownS.E. & LivingstonP.O. (2004). A phase II trial comparing five dose levels of BEC2 anti-idiotypic monoclonal antibody vaccine that mimics GD3 ganglioside. Vaccine22, 2904–2909.
148.
ForeroA., ShahJ., CarlisleR., TriozziP.L., LoBuglioA.F., WangW.Q., FujimoriM. & ConryR.M. (2006). A phase I study of an anti-GD3 monoclonal antibody, KW-2871, in patients with metastatic melanoma. Cancer Biotherapy & Radiopharmaceuticals21, 561–568.
149.
ChapmanP.B., WuD., RagupathiG., LuS., WilliamsL., HwuW.J., JohnsonD. & LivingstonP.O. (2004). Sequential immunization of melanoma patients with GD3 ganglioside vaccine and anti-idiotypic monoclonal antibody that mimics GD3 ganglioside. Clinical Cancer Research10, 4717–4723.
150.
SeiglerH.F., WallackM.K., VervaertC.E., BashJ.A., RobersonK.M. & StuhlmillerG.M. (1989). Melanoma patient antibody responses to melanoma tumor-associated antigens defined by murine monoclonal antibodies. Journal of Biological Response Modifiers8, 37–52.
151.
SpagnoliG.C., AdaminaM., BolliM., WeberW.P., ZajacP., MartiW., OertliD., HebererM. & HarderF. (2005). Active antigen-specific immunotherapy of melanoma: from basic science to clinical investigation. World Journal of Surgery29, 692–699.
152.
CampoliM.R., ChangC.C., KageshitaT., WangX., McCarthyJ.B. & FerroneS. (2004). Human high molecular weight-melanoma-associated antigen (HMW-MAA): a melanoma cell surface chondroitin sulfate proteoglycan (MSCP) with biological and clinical significance. Critical Reviews in Immunology24, 267–296.
153.
HockerT.L., SinghM.K. & TsaoH. (2008). Melanoma genetics and therapeutic approaches in the 21st century: moving from the benchside to the bedside. Journal of Investigative Dermatology128, 2575–2595.
154.
FangL., LonsdorfA.S. & HwangS.T. (2008). Immunotherapy for advanced melanoma. Journal of Investigative Dermatology128, 2596–2605.
155.
MuchmoreE.A. (2001). Chimpanzee models for human disease and immunobiology. Immunological Reviews183, 86–93.
156.
ChouH.H., TakematsuH., DiazS., IberJ., NickersonE., WrightK.L., MuchmoreE.A., NelsonD.L., WarrenS.T. & VarkiA. (1998). A mutation in human CMP-sialic acid hydroxylase occurred after the Homo-Pan divergence. Proceedings of the National Academy of Sciences of the USA95, 11751–11756.
157.
MuchmoreE.A., DiazS. & VarkiA. (1998). A structural difference between the cell surfaces of humans and the great apes. American Journal of Physical Anthropology107, 187–198.
158.
Brinkman-Van der LindenE.C., SjobergE.R., JunejaL.R., CrockerP.R., VarkiN. & VarkiA. (2000). Loss of N-glycolylneuraminic acid in human evolution. Implications for sialic acid recognition by siglecs. Journal of Biological Chemistry275, 8633–8640.
159.
GomaaA.I., KhanS.A., ToledanoM.B., WakedI. & Taylor-RobinsonS.D. (2008). Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World Journal of Gastroenterology14, 4300–4308.
160.
PoduriC.D. (2003). Hepatitis C virus (HCV) — a review molecular biology of the virus, immunodiagnostics, genomic heterogeneity and the role of virus in hepatocellular carcinoma. Indian Journal of Experimental Biology41, 549–562.
161.
StuhlmillerG.M. & SeiglerH.F. (1975). Characterization of a chimpanzee anti-human melanoma antiserum. Cancer Research35, 2132–2137.
162.
LeongS.P., HornungM.O. & KrementzE.T. (1976). Immunofluorescent studies on chimpanzee humoral responses to human melanoma cells. Oncology33, 246–249.
163.
StuhlmillerG.M. & SeiglerH.F. (1977). Enzymatic susceptibility and spontaneous release of human melanoma tumor-associated antigens. Journal of the National Cancer Institute58, 215–221.
164.
AdlercreutzH., MuseyP.I., FotsisT., BannwartC., WahalaK., MakelaT., BrunowG. & HaseT. (1986). Identification of lignans and phytoestrogens in urine of chimpanzees. Clinica Chimica Acta158, 147–154.
165.
MuseyP.I., AdlercreutzH., GouldK.G., CollinsD.C., FotsisT., BannwartC., MakelaT., WahalaK., BrunowG. & HaseT. (1995). Effect of diet on lignans and isoflavonoid phytoestrogens in chimpanzees. Life Sciences57, 655–664.
166.
WongM.C., EmeryP.W., PreedyV.R. & WisemanH. (2008). Health benefits of isoflavones in functional foods? Proteomic and metabonomic advances. Inflammopharmacology16, 235–239.
167.
WardH., ChapelaisG., KuhnleG.G., LubenR., KhawK.T. & BinghamS. (2008). Lack of prospective associations between plasma and urinary phytoestrogens and risk of prostate or colorectal cancer in the European Prospective into Cancer-Norfolk study. Cancer Epidemiology Biomarkers & Prevention17, 2891–2894.
168.
Anon. (2009). RxList Internet Drug Index. Available at: http://www.rxlist.com (Accessed 10.06.09). Atlanta, GA, USA: WebMD, Inc.
VugmeysterY., HowellK., McKeeverK., CombsD. & Canova-DavisE. (2003). Differential in vivo effects of rituximab on two B-cell subsets in cynomolgus monkeys. International Immunopharmacology3, 1477–1481.
172.
VugmeysterY. & HowellK. (2004). Rituximabmediated depletion of cynomolgus monkey B cells in vitro in different matrices: possible inhibitory effect of IgG. International Immunopharmacology4, 1117–1124.
173.
VugmeysterY., HowellK., BakshlA., FloresC. & Canova-DavisE. (2003). Effect of anti-CD20 monoclonal antibody, Rituxan, on cynomolgus monkey and human B cells in a whole blood matrix. Cytometry A52, 101–109.
MordentiJ., CuthbertsonR.A., FerraraN., ThomsenK., BerleauL., LickoV., AllenP.C., ValverdeC.R., MengY.G., FeiD.T., FourreK.M. & RyanA.M. (1999). Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. Toxicologic Pathology27, 536–544.
PhanD.T., GidaliJ., FeherI., HarsanyiV., PetranyiG.G. & HollanS.R. (1987). Comparison of efficiency of complements from various species for T-cell depletion from Cercopithecus aethiops bone marrow with Campath-1 MoAb in vitro. Haematologia (Budapest)20, 203–213.
178.
PhanD.T., BartaE., GidaliJ., FeherI., HarsanyiV., PetranyiG.G. & HollanS.R. (1987). T-cell depletion of Cercopithecus aethiops monkey bone marrow with Campath-1 monoclonal antibody and complement. Haematologia (Budapest)20, 155–163.
179.
PhanD.T., BenczurM., GidaliJ., FeherI., HarsanyiV., NemesL., PetranyiG. & HollanS.R. (1989). Cercopithecus aethiops monkey as a reliable model for in vitro study of T cell depletion of bone marrow with Campath-1 plus complement. Folia Haematologica (Leipzig, Germany)116, 97–106.
180.
HaleG., SwirskyD.M., HayhoeF.G. & WaldmannH. (1983). Effects of monoclonal anti-lymphocyte antibodies in vivo in monkeys and humans. Molecular Biology & Medicine1, 321–334.
XuL., ZuchC.L., LinY.S., ModiN.B. & LumB.L. (2008). Pharmacokinetics and safety of bevacizumab administered in combination with cis-platin and paclitaxel in cynomolgus monkeys. Cancer Chemotherapy & Pharmacology61, 607–614.
184.
GaudreaultJ., ShiuV., BricarelloA., ChristianB.J., ZuchC.L. & MounhoB. (2005). Concomitant administration of bevacizumab, irinotecan, 5-fluorouracil, and leucovorin: nonclinical safety and pharmacokinetics. International Journal of Toxicology24, 357–363.
185.
GerberH.P. & FerraraN. (2005). Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Research65, 671–680.
KurokiM., HuangJ., ShibaguchiH., TanakaT., ZhaoJ., LuoN., HachimineK., KinugasaT., MaekawaS., EnatsuS., HamanakaW., FukamiT. & KurokiM. (2006). Possible applications of antibodies or their genes in cancer therapy. Anticancer Research26, 4019–4025.
188.
SchusterM., NechanskyA. & KircheisR. (2006). Cancer immunotherapy. Biotechnology Journal1, 138–147.
189.
SharkeyR.M. & GoldenbergD.M. (2006). Targeted therapy of cancer: new prospects for antibodies and immunoconjugates. CA: Cancer Journal for Clinicians56, 226–243.
190.
SternM. & HerrmannR. (2005). Overview of monoclonal antibodies in cancer therapy: present and promise. Critical Reviews in Oncology/Hematology54, 11–29.
191.
LoiselS., OhresserM., PallardyM., DaydeD., BerthouC., CartronG. & WatierH. (2007). Relevance, advantages and limitations of animal models used in the development of monoclonal antibodies for cancer treatment. Critical Reviews in Oncology/Hematology62, 34–42.
BeyersdorfN., HankeT., KerkauT. & HunigT. (2006). CD28 superagonists put a break on autoimmunity by preferentially activating CD4+CD25+ regulatory T cells. Autoimmunity Reviews5, 40–45.
194.
StebbingsR., FindlayL., EdwardsC., EastwoodD., BirdC., NorthD., MistryY., DilgerP., LiefoogheE., CludtsI., FoxB., TarrantG., RobinsonJ., MeagerT., DolmanC., ThorpeS.J., BristowA., WadhwaM., ThorpeR. & PooleS. (2007). “Cytokine storm” in the phase I trial of monoclonal antibody TGN1412: better understanding the causes to improve preclinical testing of immunotherapeutics. Journal of Immunology179, 3325–3331.
195.
SuntharalingamG., PerryM.R., WardS., BrettS.J., Castello-CortesA., BrunnerM.D. & PanoskaltsisN. (2006). Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. New England Journal of Medicine355, 1018–1028.
196.
ChapmanK. (2006). Opportunities for reducing the use of non-human primates in the development of monoclonal antibodies — a workshop report, 30 pp. Available at: http://www.nc3rs.org.uk/downloaddoc.asp?id=515 (Accessed 11.08.09). London, UK: National Centre for the Replacement, Refinement and Reduction of Animals in Research.
PuenteX.S., Gutierrez-FernandezA., OrdonezG.R., HillierL.W. & Lopez-OtinC. (2005). Comparative genomic analysis of human and chimpanzee proteases. Genomics86, 638–647.
202.
GlazkoG., VeeramachaneniV., NeiM. & MakalowskiW. (2005). Eighty percent of proteins are different between humans and chimpanzees. Gene346, 215–219.
203.
CalarcoJ.A., XingY., CaceresM., CalarcoJ.P., XiaoX., PanQ., LeeC., PreussT.M. & BlencoweB.J. (2007). Global analysis of alternative splicing differences between humans and chimpanzees. Genes & Development21, 2963–2975.
204.
AhmedJ., GuntherS., MollerF. & PreissnerR. (2007). A structural genomics approach to the regulation of apoptosis: chimp vs. human. Genome Informatics18, 22–34.
205.
VarkiA. (2000). A chimpanzee genome project is a biomedical imperative. Genome Research10, 1065–1070.
206.
MillerB.A., ScoppaS.M. & FeuerE.J. (2006). Racial/ethnic patterns in lifetime and age-conditional risk estimates for selected cancers. Cancer106, 670–682.
207.
RussellW.M.S. & BurchR.L. (1959). The Principles of Humane Experimental Technique, 238 pp. London, UK: Methuen.
